Focused on Hematology
Dedicated to Patients

Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation

Innovation

There are millions of patients whose lives are affected by
and suffer from hematologic diseases. From rare blood
disorders to widespread, chronic disorders, there are a
host of diseases that require creative, new approaches
and a willingness to pioneer new fields of biology.

learn more about our science

Impact

We are committed to turning scientific discoveries into
useful therapies that will have a meaningful impact on
the lives of patients and their families. We are pursuing
the development of treatments that will potentially save
lives, alleviate suffering and enable patients to lead
vibrant lives.

learn more about our pipeline

Inspiration

Our team of talented scientists and industry veterans draws
motivation and meaning from the work we do and the patients
we hope to help. We are also inspired by a shared drive, tireless
dedication and desire to make a difference that brings us together
as colleagues.

learn more about our team

In The News

Disc Medicine Expands Hematology P…

Clinical-Stage Program is Positioned to Enter Phase 2 Study in Erythropoietic Protoporphyria (EPP) CAMBRIDGE, Mass. (May 27, 2021) – Disc Medicine, Inc. announced…

Disc Medicine to Present at the Eu…

CAMBRIDGE, Mass. (May 24, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for…

Disc Medicine to Present at the Je…

CAMBRIDGE, Mass. (May 21, 2021) – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious…

Focused on Hematology Dedicated to Patients